Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.

Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.

Brief description of study

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552) evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F) Injection PET MPI, prior to ICA. Patients can be considered for enrolment if: - They are being scheduled via written documentation at the time of enrolment to undergo ICA, and - They have undergone a clinically indicated SPECT study which meets all study-specified imaging and stress testing criteria, or are willing to undergo SPECT MPI for the purposes of the clinical study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Coronary Artery Disease
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 18 Feb 2020. Study ID: 832345

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center